Effect of an RNA interference drug on the synthesis of proprotein convertase subtilisin/kexin type 9 (PCSK9) and the concentration of serum LDL cholesterol in healthy volunteers: a randomised, single-blind, placebo-controlled, phase 1 trial
Kevin Fitzgerald, Maria Frank-Kamenetsky(Alnylam Pharmaceuticals (United States)), Svetlana Shulga‐Morskaya(Alnylam Pharmaceuticals (United States)), Abigail Liebow(Alnylam Pharmaceuticals (United States)), Brian R. Bettencourt(Alnylam Pharmaceuticals (United States)), Jessica E. Sutherland(Alnylam Pharmaceuticals (United States)), Renta Hutabarat(Alnylam Pharmaceuticals (United States)), Valerie A. Clausen(Alnylam Pharmaceuticals (United States)), Verena Karsten(Alnylam Pharmaceuticals (United States)), Jeffrey Cehelsky(Alnylam Pharmaceuticals (United States)), Saraswathy V. Nochur(Alnylam Pharmaceuticals (United States)), Victor Kotelianski(Alnylam Pharmaceuticals (United States)), Jay D. Horton(The University of Texas Southwestern Medical Center), Timothy Mant(Guy's Hospital), Joseph Chiesa(Covance (United Kingdom)), James M. Ritter(IQVIA (United Kingdom)), Malathy Munisamy(Covance (United Kingdom)), Akshay Vaishnaw(Alnylam Pharmaceuticals (United States)), Jared Gollob(Alnylam Pharmaceuticals (United States)), Amy Simon(Alnylam Pharmaceuticals (United States))
Cited by 573
Abstract
Related Papers
No related papers found
Powered by citation graph analysis